Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma

Brian Slomovitz; David Cibula; Murat Gultekin; Mansoor Mirza; Beata Mackowiak-Matejczyk; Alexandra Taylor; Ignacio Romero; Nicoletta Colombo; Jacob Korach; Jianqing Zhu; Lucy Gilbert; Kosei Hasegawa; Jae-Weon Kim; Sally Baron-Hay; Vicky Makker; Robert L. Coleman; Robert J. Orlowski; Xuan Zhou; Vivek Khemka; Sandro Pignata

doi:10.1136/ijgc-2022-igcs.525

Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma

Brian Slomovitz
, David Cibula
, Murat Gultekin
, Mansoor Mirza
, Beata Mackowiak-Matejczyk
, Alexandra Taylor
, Ignacio Romero
, Nicoletta Colombo
, Jacob Korach
, Jianqing Zhu
, Lucy Gilbert
, Kosei Hasegawa
, Jae-Weon Kim
, Sally Baron-Hay
, Vicky Makker
, Robert L. Coleman
, Robert J. Orlowski
, Xuan Zhou
, Vivek Khemka
, Sandro Pignata

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	A230-A230
Number of pages	1
Journal	International Journal of Gynecological Cancer
Volume	32
DOIs	https://doi.org/10.1136/ijgc-2022-igcs.525
Publication status	Published - Dec 2022

Access to Document

10.1136/ijgc-2022-igcs.525

Cite this

Slomovitz, B., Cibula, D., Gultekin, M., Mirza, M., Mackowiak-Matejczyk, B., Taylor, A., Romero, I., Colombo, N., Korach, J., Zhu, J., Gilbert, L., Hasegawa, K., Kim, J.-W., Baron-Hay, S., Makker, V., Coleman, R. L., Orlowski, R. J., Zhou, X., Khemka, V., & Pignata, S. (2022). Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma. International Journal of Gynecological Cancer, 32, A230-A230. https://doi.org/10.1136/ijgc-2022-igcs.525

@article{41d99745770c42ed9900691ba7a877b0,

title = "Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma",

author = "Brian Slomovitz and David Cibula and Murat Gultekin and Mansoor Mirza and Beata Mackowiak-Matejczyk and Alexandra Taylor and Ignacio Romero and Nicoletta Colombo and Jacob Korach and Jianqing Zhu and Lucy Gilbert and Kosei Hasegawa and Jae-Weon Kim and Sally Baron-Hay and Vicky Makker and Coleman, \{Robert L.\} and Orlowski, \{Robert J.\} and Xuan Zhou and Vivek Khemka and Sandro Pignata",

year = "2022",

month = dec,

doi = "10.1136/ijgc-2022-igcs.525",

language = "English",

volume = "32",

pages = "A230--A230",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Elsevier Inc.",

}

Slomovitz, B, Cibula, D, Gultekin, M, Mirza, M, Mackowiak-Matejczyk, B, Taylor, A, Romero, I, Colombo, N, Korach, J, Zhu, J, Gilbert, L, Hasegawa, K, Kim, J-W, Baron-Hay, S, Makker, V, Coleman, RL, Orlowski, RJ, Zhou, X, Khemka, V & Pignata, S 2022, 'Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma', International Journal of Gynecological Cancer, vol. 32, pp. A230-A230. https://doi.org/10.1136/ijgc-2022-igcs.525

Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma. / Slomovitz, Brian; Cibula, David; Gultekin, Murat et al.
In: International Journal of Gynecological Cancer, Vol. 32, 12.2022, p. A230-A230.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Keynote-c93/gog-3064/engot-en15

T2 - Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma

AU - Slomovitz, Brian

AU - Cibula, David

AU - Gultekin, Murat

AU - Mirza, Mansoor

AU - Mackowiak-Matejczyk, Beata

AU - Taylor, Alexandra

AU - Romero, Ignacio

AU - Colombo, Nicoletta

AU - Korach, Jacob

AU - Zhu, Jianqing

AU - Gilbert, Lucy

AU - Hasegawa, Kosei

AU - Kim, Jae-Weon

AU - Baron-Hay, Sally

AU - Makker, Vicky

AU - Coleman, Robert L.

AU - Orlowski, Robert J.

AU - Zhou, Xuan

AU - Khemka, Vivek

AU - Pignata, Sandro

PY - 2022/12

Y1 - 2022/12

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000899252300481&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1136/ijgc-2022-igcs.525

DO - 10.1136/ijgc-2022-igcs.525

M3 - Meeting Abstract

SN - 1048-891X

VL - 32

SP - A230-A230

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

ER -

Slomovitz B, Cibula D, Gultekin M, Mirza M, Mackowiak-Matejczyk B, Taylor A et al. Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma. International Journal of Gynecological Cancer. 2022 Dec;32:A230-A230. doi: 10.1136/ijgc-2022-igcs.525

Keynote-c93/gog-3064/engot-en15: Phase 3, Randomized, Open-label Study of First-line Pembrolizumab Versus Platinum-doublet Chemotherapy in Mismatch Repair Deficient Advanced Or Recurrent Endometrial Carcinoma

Access to Document

Other files and links

Cite this